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ABSTRACT
Background: Traditional methods for detecting positive blood cultures include the usc of
broth bottles with sensitive indicators for growth. These techniques can take 24-48 hours
to signal a positive test. Another 24 hours arc often required to determine the species of
the organism. The use of rapid diagnostic testing for Candida species bloodstream
infections provides accurate species identification in less than two hours.
Objective: Evaluate the time to appropriate antifungal therapy in patients in which rapid
diagnostic testing was utilized.
Methods: This study was a retrospective, observational cohort of patients who had
positive blood cultures for Candida species and had rNA FISH@ technology used as a
rapid diagnostic test. Patients admitted to either Sidney & Lois Eskenazi or Wishard
Memorial Hospital during the time frame of January 1,2012 to November 30,2014 were
eligible for inclusion. Patients had to have at least one positive blood culture for Calldida
species. The following data was collected: demographics, microbiologic data,
antimicrobial regimen, time to appropriate antimicrobial therapy, hospital length of stay
and mortality.
Results: Of the 27 blood cultures in which PNA FISH® technology was used, the
average time to appropriate antifungal therapy was 15.24 ± 17.7 hours. Therapy was
appropriately initiated or adjusted after the PNA FISH® results in 330;;) of patients (9/27).
The mean hospital length of stay was 24.4 ± 18.8 days and the mean intensive care unit
(lCU) length of stay was 15 ± 20.7 days. All-cause mortality was 22.2°;;) (6/27).
Conclusion: This study showed that the average time to appropriate antifungal therapy of
15.24 hours was comparable to current published studies. Due to the small number of
patients in which therapy was appropriately adjusted after the PNA FISH®, it may be
beneficial to educate healthcare providers about the usefulness of the PNA FISH(!y and
how this technology may be utilized to enhance clinical practice and potentially improve
patient outcomes.
BACKGROUND
Candidemia is the fourth most common cause of nosocomial bloodstream
infections in the United States. Candida species are the most common cause of invasive
fungal infections in humans.' Common risk factors for candidemia include: central
venous catheters, parenteral nutrition, renal replacement therapy, immunosuppressive
agents and broad-spectrum antibiotic use. Invasive candidiasis has an estimated mortality
01'47%.'
Traditional methods for detecting positive blood cultures for an organism include
the use of broth bottles with sensitive indicators for growth. These techniques can take
24-48 hours to indicate a positive result. Then, an additional 24 hours is often required to
determine the species of the organism. One can then expect another 24 hours for
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antimicrobial susceptibility testing.2 The use of rapid diagnostic testing for Candida
species bloodstream infections may significantly reduce the time to appropriate
antimicrobial therapy by providing correct species identification in less than two hours.
Examples of rapid diagnostic tests currently available include: PNA FISH (AdvanDx),
PCR (BD GeneOhm and Cepheid) and MALDI-TOF (Bruker Daltonics Inc.j'
The Yeast Traffic Light@ PNA FISH@ (AdvanDx, Woburn, MA) provides rapid
identification of five different Candida species. This technology is a fluorescence in situ
hybridization (FISH) method which uses PNA probes to hybridize to specific ribosomal
RNA sequences of C. albicans, C. parapsilosis, C. tropicalis, C. glabrata and C. krusci.
This test provides identification of C. a/Means and/or C. parapsilosis, C. glabrata and/or
C. krusei and C. tropiealis from positive blood culture smears by signaling a different
color for each organism under fluorescence microscope examination. C. albicans and/or
C. parapsilosis will be signaled by a green-positive, C. glabrata and/or C. krusei will
signal as a red-positive and C. tropiealis will signal as a yellow-positive. The time to a
positive result is approximately 90 minutes." Figure I is a sample interpretation of the
results of the assay using a fluorescence microscope.
The Yeast Traffic Light@ PNA FISH@ (AdvanDx, Woburn, MA) is distributed as
a kit containing a fixation solution, a yeast traffic light PNA, a 60x wash solution and a
mounting medium. The test is performed by combining a mixture of fluorescein and
rhodamine-labeled PNA probes to a blood smear. Hybridization is performed for 30
minutes at 55° C which is followed by a post-hybridization wash with the wash solution.
It is then prepared onto the mounting medium and able to be examined via fluorescence
. 1microscopy ..
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Limitations of this test include the inability to differentiate between C. albicans or
C. parapsilosis and C. glahrata or C. krusei. The test also cannot differentiate Candida
species in cultures with mixed growth. The assay requires further isolation on solid
growth media to detel111ine correct species identification. An additional limitation
includes a potential false-positive result that may occur due to the sequence similarity of
C. glabrata to C. nivaricnsis and C. bracarensis, which may lead to a t~dse-positive (red).
A false-positive (green) may also occur with C. orthopsilosis and C. metapsilosis due to
their similarity to C. parapsilosis.3 Finally, the assay does not provide susceptibility
information.
The detection limit for all five Candida species has been determined to be
approximately 105 cfu/mL by serial dilutions of positive cultures which is consistent with
traditional staining techniques. Specificity testing on 75 laboratory and reference cultures
containing Candida species were all proven to show the correct organism to be isolated.
Reproducibility testing of 19 isolates showed 98.7<% total agreement across three
different testing sites.3
Hall and colleagues performed a study on 216 blood cultures positive for Calldida
species." Of these cultures, the Yeast Traffic Light@ rNA FISH@ identified the correct
Candida species 96% of the time (207/216). Using a 30-minute hybridization time, the
Yeast Traffic Light@ rNA FISH@ correctly identified 100% of C. albicans (39/39), 94%
of C. parapsilosis (31/33), 100<%of C. glahrata (34/34), 100<Yof C. krusei (24/24) and
94% of C. tropicalls (3 1/33). They found equivalent results using a 90-minute
hybridization time.4 Although there is an abundance of data regarding the specificity and
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sensitivity of the PNA FISH® assay, the clinical application has only been briefly
examined in recent years.
Heil and colleagues compared time to targeted therapy, hospital length of stay and
in-hospital mortality before the implementation of the rNA FISH® technology and after.
They calculated a statistically signiticant shorter mean time to targeted therapy with the
PNA FISH® of 0.6 day or 14.4 hours compared to 2.3 days with traditional techniques
(p=O. 0016). Hei Iand co IIeagues found no stati sticall y signi fican t difference in hospi ta I
length of stay or in-hospital mortality between the two groups."
Aitken and colleagues found the average time to identification of yeast by
traditional laboratory methods to be 2.2 ± 1.3 days. The authors then performed a 5,000
person Monte Carlo simulation, in which they found that the average time to initiation of
antifungal therapy was 3.5 ± 2.1 days with traditional methods as compared to 2.6 ± 1.3
days with the PNA FISHcID.
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NEED FOR THE STUDY
The current Infectious Disease Society of America guidelines for the management
of candidiasis recommend initial selection of antifungal therapy based on species
identification, making species identification key for clinical decision making.' Most
patients are not initiated on an antifungal until yeast identification after a Gram stain.
Appropriate pathogen-specific therapy is generally not initiated until the Candida species
is identified.' The rNA FISH@ may serve as a reliable tool to determine speciation
within 90 minutes which is much faster than traditional methods of detection which can
take three to five days.
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One disadvantage of the PNA FrSH® is cost. The equipment cost is
approximately $1,000 and $30-$80 is required per test.
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This raises the question of
whether the cost is worth the potential outcome. A goal of the current study was to
determine the effect of the rNA FISl-ICJ.Don time to appropriate antifungal therapy,
appropriate therapy modification and the impact on overall clinical outcomes for patients.
Limited literature is currently available regarding the use of PNA FISH® for
candidemia and subsequent clinical outcomes. Therefore, it is beneficial to explore the
effect of rNA FISH® technology on time to appropriate antifungal therapy, hospital
length of stay and mortality.
OBJECTIVE
The primary objective in this study was to determine the time to appropriate
antifungal therapy in patients with Candida species bloodstream infections in which the
PNA FrSH® assay was utilized.
Secondary objectives include: the percent of patients in which antimicrobial
therapy was appropriately adjusted after the PNA FISH@ results, total hospital length of
stay, intensive care unit length of stay and all-cause mortality.
METHODS
Study Design: This study was a retrospective, observational cohort of patients with
positive blood cultures for Candida species and had rNA rISH@ technology used as a
rapid diagnostic test on the blood culture specimens. This study received exemption
status from the Indiana University Institutional Review Board.
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The process for detennining final Candida speciation for positive blood cultures at
Eskenazi Health is as follows: After a positive Gram stain for yeast is identified from a
blood culture, the rNA FISH® is perfomled by the laboratory. These results are then
reported to the physician. The final step in the process is to complete standardized testing
to obtain final speciation using the VITEK2 system.
Inclusion Criteria: Patients admitted to either Sidney & Lois Eskenazi or Wishard
Memorial Hospital during the time frame of January 1,2012 to November 30,2014 were
eligible for inclusion. Patients had to have at least one positive blood culture for Candida
species. If patients had multiple positive cultures for the same Candida species during the
same admission, only the first positive culture was included.
Exclusion Criteria: Patients were excluded if they did not have the PNA FISH(IDrapid
diagnostic test used on their blood culture. Patients who were younger than 18 years of
age, pregnant or prisoners were also excluded.
Data Source: Data was extracted from electronic medical records of eligible patients
admitted to Sidney & Lois Eskenazi Hospital or Wishard Memorial Hospital during the
time frame of January 1,2012 to November 30,2014. The data collected included: age,
gender, allergies, past medical history, location of the blood draw, hospital length of stay,
leu length of stay, microbiologic data, antimicrobial regimen details, time to appropriate
antifungal therapy and all-cause mortality during hospital admission.
Definition ojAppropriate Ant(jllflga/ Therapy: In accordance with the Infectious Disease
Society of America's clinical practice guidelines for the treatment of candidiasis,
appropriate antifungal therapy for C. ntbicans, C. parapsi/osis. and C. tropiea/is was
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defined as fluconazole and appropriate antifungal therapy for C. glabrata and C. krusei
was defined as an echinocandin I (the formulary option being caspofungin at Eskenazi
Health). If the patient was started on appropriate empiric therapy then de-escalated based
on susceptibilities, time to appropriate therapy was then based on appropriate empiric
therapy.
Statistical Ana~vsis: Descriptive statistics were utilized for the primary and secondary
objectives of this study.
RESULTS
A total of 52 blood cultures in 52 patients which were positive for Candida
species were evaluated. Of these, 25 blood cultures were excluded because rNA FISH@
technology was not used to analyze the blood culture. This left a sample of 27 blood
cultures positive for Candida species in which rNA FISH@ technology was used. Table
I outlines patient demographic information.
Figure 2 shows the number of different Candida species identified by the rNA
FISH® compared to the final speciation results. The species determined by the rNA
FISH® were consistent with the final speciation results 100% of the time (27/27).
Susceptibility testing for every Candida species blood cultures is not routine practice at
Eskenazi Health, however, susceptibility testing was performed on seven of the positive
cultures: five C. glabrata isolates, one C. krusei isolate and one C. parapsi!osis isolate.
The average time to appropriate anti fungal therapy was 15.24 ± 17.7 hours. The
mean hospital length of stay was 24.4 ± 18.8 days. Twenty-three of 27 patients (8YYt»)
were admitted to the leu during their hospital stay, while four patients stayed on the
general medical units. Of the K'U patients, the mean leU length of stay was 15 ± 20.
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days. All-cause mortality was 22.2% (6/27). Table 2 outlines the primary and secondary
objectives. Out of the 27 included blood cultures, the infectious diseases consult service
was formally consulted and had documented recommendations in 24/27 of the positive
cultures. The recommendations were accepted in all 24 cases in which the infectious
diseases consult service was consulted.
Appropriate empiric therapy was started in 92.6(10 of positive blood cultures
(25/27). Therapy was initiated or changed after the rNA FISH@ for 33°;;) of positive
blood cultures (9/27). Table 3 outlines the timing of antifungal therapy initiation and
Table 4 describes the antifungal therapy regimens by Candida species in all 27 positive
blood cultures.
DISCUSSION
Heil and colleagues evaluated the PNA FISH® assay and its impact on the
treatment of Candida species bloodstream infections.
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The study evaluated the time to
species identification, time to targeted therapy, clinical outcomes (culture clearance,
hospital length of stay and hospital mortality) and the cost effectiveness of the rNA
FISH® before and after test implementation. The results found a statistically significant
decrease in time to targeted therapy after implementation of PNA FISI-ICID.In the pre-
implementation of the rNA FISH® group, time to targeted therapy was 2.3 days
compared to 0.6 day (14.4 hours) in the post_implementation of the rNA FISI-{(R)group
(p=O.OO16).5 These findings are comparable to the enrrent study findings for average
time to appropriate antifungal therapy of 15.24 ± 17.7 hours.
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The study done by Heil and colleagues found no statistically significant difference
in hospital length of stay between the pre-implementation group and the post-
implementation group (25 days versus 12 days; p==0.82). This study also found no
statistically significant difference in mortality between the pre_implementation group and
the post_implementation group (19% versus 5%; p>0.99).
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Hospital length of stay was
much longer in the current study compared to the study done by Heil and colleagues. In
terms of mortality, the current study is comparable to the study done by Heil and
colleagues (19% compared to 22.2%) with the current study's measure of all-cause
mortality being slightly higher.
Aitken and colleagues performed a study to assess the role of rapid diagnostic
technologies in antifungal stewardship.6 The study included 162 patients with culture
proven eandidemia. The researchers evaluated the time to initiation of therapy and tound
the average to be 3.5 ± 2.1 days. Using this data they compared their findings to a 5,000
person Monte Carlo simulation. They found that the average time to initiation of therapy
was 2.6 ± 1.3 days with the rNA FISH®.6 The average time to initiation of therapy was
much higher than what was found in the current study (2.6 ± 1.3 days compared to 15.24
± 17.7 hours).
The cun-ent study had multiple limitations including retrospective design, small
sample size and being a single center study. In 2012, a change was made in the reporting
strategy for positive cultures by removing the wording "by rNA FISHC({J"as it was
believed the statement may lead to misinterpretation of the results. This may have
resulted in exclusion of cultures in which the rNA FISH@ was used. The authors
assumed the rNA FISH(I{)was used if the medical record notes indicated C. albtcans
10
and/or C. parapsilosis or C. glabrata and/or C. krusel. There were multiple potential
inconsistencies in result reporting as provided by the medical records.
CONCLUSIONS
In conclusion, this study found an average time to appropriate therapy of 15.24 ±
17.7 hours in patients in which PNA FISH® technology was used as a rapid diagnostic
test for Candida species bloodstream infections. This result is comparable to the results
of a study done by Heil and colleagues, in which the average time to targeted antifungal
therapy after PNA FlSH® implementation was 14.4 hours.
It would be beneficial in the future to evaluate the time to appropriate antifungal
therapy before and after PNA FISH@ implementation. This would provide the ability to
run data analyses and determine statistical significance, as this study was limited by only
being able to evaluate descriptive statistics.
This study found that only 33°/cl of positive blood cultures had therapy changed or
initiated after the PNA FrSH@ results were reported to the physician. This shows a
possible area for improvement in patient care. Educational efforts should be expanded to
health care providers to provide infoffilation on the use of the rNA FISH® as a rapid
diagnostic test. This may improve time to appropriate therapy in patients with candidemia
in which species identification is key in determining appropriate antifungal therapy.
II
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Table 1: Patient Demographics
n=27
Age (years)" 57.15 (16.9)
Maleb 19 (70.4)
Primary teamb Medical: 20 (74)
Surgical: 5 (19)
Other: 2 (7)
a = data reported as average (± SD)
b = data reported as n (%)
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Table 2: Primary and Secondary Objective Outcomes
n=27
Time to appropriate therapy (hours)" 15.24(17.7)
Appropriate therapy after PNA FISH®b 9 (33)
Not appropriate therapy after PNA FISH®l) I (3.7)
Hospital length of stay (days)" 24.4 (18.8)
ICU admissiol~h 23 (85.2)
ICU length of stay (days)" 15 (20.7)
All-cause mortality" 6 (22.2)
a = data reported as average (± SD)
b = data reported as n (%)
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Table 3: Timing of Antifungal Therapy Initiation
n=27 1
Therapy changed or initiated after rNA FISH(f~a 9 (33)
Therapy started after final speciation" 7 (26)
Therapy started before physician notification
a 7 (26)
No physician notification
a 4 (15)
a= data reported as n (%)
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Table 4: Empiric and Final Antifungal Therapv
Species Empiric Therapy Final Therapy
n (%)
c. albicans Fluconazole Fluconazole 7 (26)
C. glabrata Caspofungin Caspofungin
6 (22)
Caspofungin Voriconazole 3 (11)
Caspofungin Fluconazole 1 (3.7)
Fluconazole Caspofungin I (3.7)
None None
1 (3.7)
C. krusei Voriconazole
Voriconazole I (3.7)
C. parapsilosts Fluconazole
Fluconazole 4 (15)
Caspofungin Fluconazole
2 (7.5)
C. tropicalis Fluconazole Fluconazole
1 (3.7)
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Figure 1.
C. albicans (top left), C. tropicalis (top middle), C glabrata (top right), mixed positive
(bottom left) and negative (bottom middle) adapted from:
Yeast Traffic Light@ PNA FISH@ [package insert]. Woburn, MA: AdvanDx; 2011.
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Figure 2: Species Identification
Species Identification
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